WST Deadline: Rosen Law Firm Urges West Pharmaceutical Services, Inc. (NYSE: WST) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

News > Business News

Audio By Carbonatix

10:11 AM on Saturday, June 28

The Associated Press

NEW YORK--(BUSINESS WIRE)--Jun 28, 2025--

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025. West describes itself as a “medical supplies company specializing in packaging components, containment solutions, and delivery systems for injectable drugs.”

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that West Pharmaceutical Services, Inc. (NYSE: WST) Misled Investors Regarding its Business Operations.

According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products (“HVP”) portfolio; (2) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West’s profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West’s exit from continuous glucose monitoring (“CGM”) contracts with long-standing customers; and (4) as a result of the foregoing, defendants’ positive statements about West’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against West Pharmaceutical Services, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 7, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250628486201/en/

CONTACT: Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]